Technical Analysis for PRTG - Portage Biotech Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | -1.76% | |
| NR7 | Range Contraction | -1.76% | |
| Narrow Range Bar | Range Contraction | -1.76% | |
| Wide Bands | Range Expansion | -1.76% | |
| Oversold Stochastic | Weakness | -1.76% | |
| Fell Below 50 DMA | Bearish | 0.54% | |
| MACD Bearish Centerline Cross | Bearish | 0.54% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 24 hours ago |
| 50 DMA Resistance | about 24 hours ago |
| Down 3% | about 24 hours ago |
| Fell Below Previous Day's Low | about 24 hours ago |
| Down 2 % | about 24 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/26/2024
Portage Biotech Inc. Description
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Immunology Solid Tumors Immune System Antibodies Antiviral Drug Interferon Acute Kidney Injury Biotechnology Products Natural Killer T Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.8 |
| 52 Week Low | 2.098 |
| Average Volume | 2,209,972 |
| 200-Day Moving Average | 7.23 |
| 50-Day Moving Average | 5.81 |
| 20-Day Moving Average | 6.27 |
| 10-Day Moving Average | 5.85 |
| Average True Range | 0.91 |
| RSI (14) | 46.24 |
| ADX | 42.54 |
| +DI | 29.22 |
| -DI | 16.07 |
| Chandelier Exit (Long, 3 ATRs) | 5.40 |
| Chandelier Exit (Short, 3 ATRs) | 8.03 |
| Upper Bollinger Bands | 7.47 |
| Lower Bollinger Band | 5.06 |
| Percent B (%b) | 0.21 |
| BandWidth | 38.32 |
| MACD Line | -0.08 |
| MACD Signal Line | 0.06 |
| MACD Histogram | -0.1362 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.18 | ||||
| Resistance 3 (R3) | 6.19 | 5.99 | 6.08 | ||
| Resistance 2 (R2) | 5.99 | 5.84 | 5.99 | 6.05 | |
| Resistance 1 (R1) | 5.79 | 5.75 | 5.69 | 5.78 | 6.01 |
| Pivot Point | 5.59 | 5.59 | 5.55 | 5.59 | 5.59 |
| Support 1 (S1) | 5.39 | 5.44 | 5.29 | 5.38 | 5.15 |
| Support 2 (S2) | 5.19 | 5.35 | 5.19 | 5.11 | |
| Support 3 (S3) | 4.99 | 5.19 | 5.08 | ||
| Support 4 (S4) | 4.98 |
